GlassScriptPhysician profile
Kristen Borchelt
NPI 1700238730
$8,805.95
in general payments reported to CMS, 2019-2025
28 companies · $3,889 in 2025
The $3,889 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $840 · 2022: $652 · 2023: $1,958 · 2024: $1,468 · 2025: $3,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,863 · Consulting Fee: $1,125 · Education: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,862.65 |
| Consulting Fee | $1,125.00 |
| Education | $326.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,890.93 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $1,073.60 | 2021-2025 | |
| Lilly USA, LLC | $723.79 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $571.43 | 2021-2025 | Cosentyx |
| Regeneron Healthcare Solutions, INC. | $499.64 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $435.04 | 2021-2025 | Adbry, Anzupgo |
| Ucb, INC. | $405.62 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Scientific Affairs, LLC | $400.25 | 2022-2023 | Tremfya |
| Amgen INC. | $363.62 | 2023-2024 | Otezla |
| Incyte Corporation | $363.36 | 2022-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.05 | 2023-2024 | Spevigo |
| Genzyme Corporation | $228.14 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $208.84 | 2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $205.80 | 2023-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $197.66 | 2023-2025 | Zoryve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $189.40 | 2021-2024 | |
| Sun Pharmaceutical Industries INC. | $149.17 | 2022-2025 | |
| Almirall LLC | $130.66 | 2021-2025 | Klisyri |
| Verrica Pharmaceuticals INC. | $102.89 | 2024-2025 | Ycanth |
| Vyne Pharmaceuticals INC. | $76.28 | 2021 | |
| Krystal Biotech INC | $67.55 | 2024-2025 | Vyjuvek |
| Pfizer INC. | $56.22 | 2021-2025 | |
| Dermavant Sciences, INC. | $48.70 | 2023-2024 | Vtama |
| Lnhc, INC | $47.27 | 2025 | Zelsuvmi |
| Organon LLC | $33.77 | 2025 | Vtama |
| Biofrontera INC. | $25.69 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Sandoz INC. | $18.14 | 2023 | Hyrimoz |
| Fresenius Kabi USA, LLC | $17.44 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Borchelt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.